Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Twin Capital Management Inc.

Twin Capital Management Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.8% in the 4th quarter, HoldingsChannel reports. The fund owned 31,725 shares of the biopharmaceutical company’s stock after acquiring an additional 6,093 shares during the period. Twin Capital Management Inc.’s holdings in Gilead Sciences were worth $2,570,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Altfest L J & Co. Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $210,000. Abundance Wealth Counselors purchased a new position in Gilead Sciences during the 3rd quarter valued at about $1,881,000. Toronto Dominion Bank increased its holdings in Gilead Sciences by 66.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock valued at $96,589,000 after acquiring an additional 515,191 shares in the last quarter. Mackenzie Financial Corp increased its holdings in Gilead Sciences by 8.9% during the 4th quarter. Mackenzie Financial Corp now owns 535,557 shares of the biopharmaceutical company’s stock valued at $43,385,000 after acquiring an additional 43,630 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. increased its holdings in Gilead Sciences by 11.7% during the 3rd quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the biopharmaceutical company’s stock valued at $3,147,000 after acquiring an additional 4,400 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on GILD. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada decreased their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research note on Wednesday, February 14th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $84.71.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 1.2 %

Shares of GILD traded down $0.77 during mid-day trading on Thursday, hitting $66.16. The company had a trading volume of 2,909,804 shares, compared to its average volume of 7,258,720. The business’s 50-day simple moving average is $72.25 and its 200-day simple moving average is $76.66. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 1-year low of $65.90 and a 1-year high of $87.86. The stock has a market cap of $82.37 billion, a PE ratio of 14.87, a P/E/G ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter in the previous year, the business posted $1.67 EPS. The company’s quarterly revenue was down 3.7% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.66%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.